Presentation to include clinical data from Aronora's phase 2 study of AB002, a first-in-class protein C activator enzyme that is being developed for the treatment and prevention of thrombotic and inflammatory diseases.

Enzyme that selectively targets blood clots has received FDA Fast Track designation, allowing for expedited clinical development